AU
UK
CA
NZ
IND
US
argenx SE (NASDAQ:ARGX) has announced a series of planned leadership transitions involving its executive team and Board of Directors. The company said current Chief Operating Officer Karen Massey will move into the role of Chief Executive Officer and Executive Director, while current Chief Executive …
Wall Street Zenrecently updated its assessment ofArcutis Biotherapeutics Inc. (NASDAQ:ARQT), upgrading the stock from abuyrating to astrong-buyrating in a report released on Sunday. The change followed a series of analyst updates tied to earnings performance and broader sector developments.
HUTCHMED Limited (Nasdaq:HCM) has initiated the Phase III segment of its ongoing Phase II/III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine (S+C+AG) as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in China. The first patient in this …
Mesoblast Limited (NASDAQ:MESO; ASX: MSB) announced a series of board changes following its recent Annual General Meeting, as part of an update to its governance structure aligned with the company’s transition toward a revenue-generating commercial phase.
FONAR Corporation (NASDAQ:FONR) announced it has entered into a definitive agreement with FONAR, LLC and FONARAcquisitionSub, Inc. to take the company private. Under the terms of theMergerAgreement, holders of the company’s common stock will receive USD 19.00 per share in an all-cash transaction.
Ultragenyx Pharmaceuticals (NASDAQ:RARE), a company focusing on treatments for rare genetic diseases, reported Phase 3 results for setrusumab (UX143), a monoclonal antibody for osteogenesis imperfecta (OI), that did not achieve primary endpoints.
Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) are presently covered by five research firms, resulting in a consensus recommendation ofHold. The current analyst mix includes oneSellrating, oneHoldrating, and threeBuyratings. Based on updates issued over the past year, the average twelve-month price target across covering …
Shares ofSAB Biotherapeutics, Inc. (NASDAQ:SABS)are currently followed by six research firms, with analyst coverage resulting in an average rating described asModerate Buy. According to available analyst data, one firm has issued aSellrating, four analysts have assignedBuyratings, and one has issued aStrong Buyrating. The average …
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing and manufacturing authorization for Dupixent® (dupilumab) to treat bronchial asthma in children aged 6 to 11 years. The authorization applies to pediatric patients with severe …
GE HealthCare (Nasdaq:GEHC) has signed a multi-year agreement to supply over 300 CT (computed tomography) scanners to public hospitals under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program. The deployment will cover all 38 provinces, including urban and remote regions, and is expected to …
Please wait processing your request...